J Pediatr Infect Dis 2015; 10(03): 068-075
DOI: 10.1055/s-0036-1571306
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Pharmacologic and Epidemiologic Study of the Course of Influenza and Other Acute Respiratory Viral Infections in Postpandemic Season in Children Younger than 18 years

Authors

  • V. A. Bulgakova

    1   Department of Scientific Research, Scientific Center of Children's Health, Moscow, Russia
  • V. F. Uchaikin

    2   Department of Infectious Diseases in Children, N. I. Pirogov Russian National Research Medical University, Moscow, Russia
  • O. V. Shamsheva

    2   Department of Infectious Diseases in Children, N. I. Pirogov Russian National Research Medical University, Moscow, Russia
  • E. A. Osipova

    3   Medical Department, JSC Pharmstandard, Moscow region, Russia
  • A. Y. Bevz

    3   Medical Department, JSC Pharmstandard, Moscow region, Russia
  • I. V. Prostyakov

    3   Medical Department, JSC Pharmstandard, Moscow region, Russia
  • V. V. Maleev

    4   Department of Infectious Diseases, Central Research Institute of Epidemiology, Moscow, Russia
Further Information

Publication History

22 June 2015

16 September 2015

Publication Date:
28 January 2016 (online)

Abstract

Introduction We assessed the epidemiologic data of influenza and other acute respiratory viral infections in children during the first postpandemic season.

Methods A retrospective analysis of randomly selected case histories of 2044 children with influenza and other ARVI.

Results Influenza A was diagnosed in 40%, influenza B in 12%, and other ARVI in 10% of cases. Umifenovir (Arbidol) was the most frequently prescribed at the prehospital and hospital stages (10.2% [207/2,025] and 65.2% [1,332/2,042], respectively).

Conclusion The results suggested that early prescription of Arbidol significantly reduced the duration of the main symptoms of influenza and ARVIs and the risk of complications.